Amgen Inc. $AMGN Stock Position Raised by Mn Services Vermogensbeheer B.V.

Key Points

• Institutional ownership increased: Mn Services Vermogensbeheer raised its Amgen stake by 1.8% to 159,819 shares valued at $67.4 million. Hedge funds and other institutions collectively own 76.5% of the company.
• Strong quarterly results and dividend: Amgen reported adjusted earnings of $6.29 per share and revenue of $10.05 billion, exceeding analyst estimates, while revenue grew 9.5% year over year. The company also paid a quarterly dividend of $2.52 per share, equivalent to a 2.5% annual yield.
• Analyst sentiment remains cautious: Amgen shares opened at $407.44, above the analyst consensus price target of $388.29. The consensus rating is “Hold,” with 16 Hold ratings, three Sells, and 11 Buy or Strong Buy ratings.

Mn Services Vermogensbeheer B.V. lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 159,819 shares of the medical research company's stock after acquiring an additional 2,800 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Amgen were worth $67,365,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Diversified Management Inc. raised its stake in shares of Amgen by 7.0% during the 3rd quarter. Diversified Management Inc. now owns 948 shares of the medical research company's stock valued at $400,000 after purchasing an additional 62 shares during the period. Dorato Capital Management boosted its stake in Amgen by 0.7% in the 3rd quarter. Dorato Capital Management now owns 4,897 shares of the medical research company's stock worth $2,023,000 after purchasing an additional 36 shares during the period. Farther Finance Advisors LLC boosted its stake in Amgen by 32.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 46,131 shares of the medical research company's stock worth $17,979,000 after purchasing an additional 11,420 shares during the period. Sapient Capital LLC grew its holdings in Amgen by 13.3% during the 3rd quarter. Sapient Capital LLC now owns 3,124 shares of the medical research company's stock valued at $1,317,000 after buying an additional 367 shares in the last quarter. Finally, CoreCap Advisors LLC grew its holdings in Amgen by 2.6% during the 3rd quarter. CoreCap Advisors LLC now owns 5,905 shares of the medical research company's stock valued at $2,476,000 after buying an additional 150 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Amgen Stock Down 1.4%

Shares of AMGN opened at $407.44 on Friday. The firm has a market cap of $220.27 billion, a P/E ratio of 25.32, a P/E/G ratio of 2.98 and a beta of 0.41. The stock has a 50 day simple moving average of $412.35 and a two-hundred day simple moving average of $371.88. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were issued a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.5%. Amgen's dividend payout ratio (DPR) is currently 62.65%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen is advancing a Phase 3 head-to-head trial of its monthly diabetes treatment, MariTide, against semaglutide-based therapy. A successful study could strengthen Amgen’s position in the highly competitive GLP-1 and obesity-treatment markets and provide a significant future growth opportunity. Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
• Positive Sentiment: Amgen’s recently announced Sjögren’s syndrome trial results appear to have supported investor sentiment, contributing to gains in the prior session. Further details on efficacy and regulatory plans will determine the longer-term impact. Amgen Announces Sjögren’s Trial Results
• Neutral Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing for AI-driven genetic testing. The investment may give Amgen access to molecular data useful for precision-medicine research, but it is unlikely to materially affect near-term earnings. Amgen Backs $30 Million Series A Round
• Neutral Sentiment: AMGN advanced about 2.6% in the prior session while the broader market declined, suggesting recent relative strength; however, this move may also have increased the potential for profit-taking. Amgen Advances While Market Declines
• Negative Sentiment: Morgan Stanley cut its price target to $359 from $362 and maintained an Equal Weight rating. Truist raised its target to $380 but kept a Hold rating. Both targets imply downside from Amgen’s recent price, reinforcing valuation concerns. Morgan Stanley Adjusts Price Target on Amgen

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on AMGN shares. Jefferies Financial Group reissued a "hold" rating and issued a $410.00 price target on shares of Amgen in a report on Wednesday, September 23rd. Canaccord Genuity Group boosted their price objective on shares of Amgen from $366.00 to $384.00 and gave the company a "hold" rating in a research note on Wednesday, August 5th. Citigroup boosted their price objective on shares of Amgen from $345.00 to $405.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. Scotiabank upped their target price on shares of Amgen from $450.00 to $500.00 and gave the stock an "outperform" rating in a report on Monday, September 28th. Finally, Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $388.29.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen's portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.